Actively Recruiting
Safety and Dose-Finding Study of Intranasal NEO100 in Children and Adolescents With Pediatric Brain Tumors
Led by Neonc Technologies, Inc. · Updated on 2026-09-15
12
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, dosing, brain tumor delivery, and pharmacokinetics of intranasal NEO100 in children and adolescents with pediatric-type high grade gliomas. This open-label Phase 1b study focuses on brain tumors such as Diffuse Midline Glioma, Diffuse hemispheric glioma, and recurrent malignant tumors of the brainstem or posterior fossa. The goal is to confirm brain tumor delivery and establish safe dosing levels in this patient group. Participants receive NEO100 through the nose following a dose titration and escalation design. The dosing starts at 192 mg four times daily and may increase up to 576 mg twice daily over 28-day cycles. Brain tumor delivery of NEO100 will be confirmed by surgical or needle biopsy only if clinically needed for patient care. Patients undergoing biopsy will receive at least four days of NEO100 treatment before the procedure. During the study, participants undergo evaluations including tissue testing for NEO100 and its metabolite perillic acid, pharmacokinetic assessments, and monitoring for adverse events. Researchers will measure the maximum tolerated dose, recommended Phase 2 dose, blood-brain barrier penetration, and drug levels in plasma. Participants will be followed for safety and treatment effects for up to six months after starting therapy.
CONDITIONS
Brief Title
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Research Team
C
Chris Beardmore
C
Chloe Richmond
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here